1 / 18

Cost-Effectiveness of Biomarker-Guided HF Therapy: Improving Heart Failure Outcomes

This program explores the cost-effectiveness of biomarker-guided therapies in heart failure management. Learn about age-adjusted hospitalization rates, diagnostic uncertainty, and the impact of selective NT-proBNP testing on costs. Join the discussion on Medscape Discuss to share your thoughts and questions on utilizing biomarkers in heart failure management.

mannix-fitzpatrick
Download Presentation

Cost-Effectiveness of Biomarker-Guided HF Therapy: Improving Heart Failure Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biomarker-GuidedHF Therapy:Is It Cost-Effective?

  2. Age-Adjusted Hospitalization Rates for Heart Failure

  3. Cost* of Heart Failure to Society

  4. Diagnostic Uncertainty Is Associated With Poor Prognosis in Acute Dyspnea

  5. Effect of Selective NT-proBNP Testing on CostsResults of the Randomized IMPROVE-CHF Trial

  6. ADHERE: Time From BNP to Time to Diuretic Treatment

  7. OPTIMIZE-HF BNP Measures and Death and Hospitalization at 1 Year

  8. Therapies With Effects on B-Type Natriuretic Peptide Levels

  9. IMPROVE HF: Improvement in Quality Measures at 24 Months (Patient Level Analysis)

  10. PROTECT: Primary Endpoint Reduction

  11. Cost-Effectiveness TIME-CHF Mortality in Reduced LVEF

  12. Biomarker -Guided Heart Failure Trials

  13. GUIDE-IT

  14. Challenges/Opportunities for Utilizing Biomarkers in the Management of Heart Failure

  15. Thank you for joining us for this program. So, what would you do? What impact does this program on biomarkers have on your practice? As a reminder please join me on Medscape Discuss, a supplementary discussion by clicking the Join the Discussion  button now. I am interested in hearing your thoughts and questions around this topic.

More Related